Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH 66 EV-to-EBITDA is 9.13 as of Aug. 14, 2026, which is 24% below its 10-year median of 11.97. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 98 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 57.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sopharma AD-Sofia's enterprise value is zł5,680 Mil.
Sopharma AD-Sofia's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł622 Mil. Therefore, Sopharma AD-Sofia's EV-to-EBITDA for today is 9.13.
The historical rank and industry rank for Sopharma AD-Sofia's EV-to-EBITDA or its related term are showing as below:
WAR:SPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.86 Med: 11.97 Max: 16.8
Current: 9.22
During the past 13 years, the highest EV-to-EBITDA of Sopharma AD-Sofia was 16.80. The lowest was 6.86. And the median was 11.97.
WAR:SPH's EV-to-EBITDA is ranked worse than 57.14% of 98
companies
in the Medical Distribution industry
Industry Median: 8.615
vs WAR:SPH: 9.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sopharma AD-Sofia's PE Ratio (TTM) for today is calculated as:
Sopharma AD-Sofia's share price for today is zł7.68.
Sopharma AD-Sofia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.895.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sopharma AD-Sofia's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's EV-to-EBITDA falls into.
Sopharma AD-Sofia's current Enterprise Value is zł5,680 Mil.
Sopharma AD-Sofia's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł622 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a EV-to-EBITDA of 9.13 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sopharma AD-Sofia. This is 24% below median its historical median of 11.97. Over the past decade, Sopharma AD-Sofia's EV-to-EBITDA has ranged from 6.86 to 16.80. According to the industry distribution chart, Sopharma AD-Sofia ranks #56 out of 98 companies in the Medical Distribution industry, placing it in the top 57.1%.
Is Sopharma AD-Sofia's EV-to-EBITDA too high?
Sopharma AD-Sofia's current EV-to-EBITDA of 9.13 is 24% below median its 10-year median of 11.97. Over the past 10 years, this metric has ranged from a low of 6.86 to a high of 16.80. The Medical Distribution industry median EV-to-EBITDA is 8.62. Sopharma AD-Sofia's value of 9.13 is 6% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #56 out of 98 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #56 out of 98 companies for EV-to-EBITDA. This places Sopharma AD-Sofia in the lower half of its industry. The industry median EV-to-EBITDA is 8.62. Sopharma AD-Sofia's value of 9.13 is 6% above this benchmark. Historically, Sopharma AD-Sofia's own EV-to-EBITDA has ranged from 6.86 to 16.80 over the past decade. While the company's 10-year median is 11.97 vs. the industry median of 8.62, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.62, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current EV-to-EBITDA of 9.13 is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sopharma AD-Sofia. For the Medical Distribution industry, the median EV-to-EBITDA is 8.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current EV-to-EBITDA is 9.13, which is 24% below median its own 10-year median of 11.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.24, compared to a current price of zł7.68 — trading 42% below its estimated fair value. The current EV-to-EBITDA is 9.13, which is 24% below median its 10-year median of 11.97 and 6% above the Medical Distribution industry median of 8.62. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EV-to-EBITDA is 9.13 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.68 is trading 42% below its estimated GF Value™ of zł13.24.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
EV-to-EBITDA: 9.13 (24% below median its 10-year median of 11.97)
GF Value™: zł13.24 vs. price of zł7.68 (42% below fair value)
Industry Position: 6% above the Medical Distribution median (#56 of 98)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
